
MHRA warns of congenital malformation risk of neo-mercazole during pregnancy
pharmafile | February 22, 2019 | News story | Medical Communications, Research and Development |Â Â MHRA, neo-mercazole, pharmaÂ
UK drug watchdog The Medicines and Healthcare products Regulatory Agency (MHRA) has warned of the potential side-effects of Neo-mercazole (carbimazole) in the treatment of hyperthyroidism, cautioning that its use can lead to an increased risk of congenital malformations during pregnancy, particularly in the first trimester.
The malformations can manifest as absence of skin; facial dysmorphism; defects of the abdominal wall and gastrointestinal tract such as exomphalos, oesophageal atresia or omphalo-mesenteric duct anomaly; and ventricular septal defect.
The agency warned women of child-bearing potential to use effective contraception while receiving the drug, and to contact their doctor as soon as possible if they are planning or due to have children.
Neo-mercazole is prescribed approximately 45,000-50,000 times per month from GP practices in NHS England, and should only be used when an underlying condition cannot be definitively treated prior to pregnancy, or in the case of occurrence or occurrence of the condition during pregnancy.
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

MHRA authorises Lynkuet for hot flushes linked to breast cancer therapy
The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised an extension to the indication …






